Orphalan
France - ParisBiotechnology
Focus: Orphalan is a publicly listed French biotechnology company specializing in rare disease treatments, with a singular focus on Wilson's disease. The company generates 100% of revenue from CUVRIOR, a copper-chelating small molecule.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3+2 this month
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Should You Work at Orphalan?
AI assessmentBest suited for rare disease specialists seeking stability and clinical focus; unsuitable for those wanting broad exposure, rapid growth, or portfolio diversification.
Why Work Here
- Singular therapeutic focus in Wilson's disease creates deep clinical expertise and tight-knit scientific teams
- Public company status provides equity upside and institutional credibility absent in early-stage biotech
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$0.378M Part DStable
Peak13.0yr
Sole revenue driver; orphan drug with 15-year LOE runway provides long-term cash security but exposes company to single-asset risk.
Help build intelligence for Orphalan
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.